We scan new podcasts and send you the top 5 insights daily.
Alex and Jennifer describe a 'pill in pocket' approach: patients keep dexamethasone at home. If they call with fever but stable vital signs, they take one dose, monitor temperature every one to two hours, and call back for recurrent fever. Many avoid admission, though repeat fever triggers evaluation.
Alex admits some patients preemptively even when outpatient dosing is possible: those living alone with limited support, patients with heart failure or chronic kidney disease, and those with high tumor burden, LDH above 1,000, or malignant effusions. The aim is faster recognition and treatment of CRS.
A critical logistical challenge for administering Tarlatumab is ensuring patients with fever (a potential sign of CRS) are not left waiting in a standard emergency room. An effective strategy involves creating a dedicated protocol so these patients are seen immediately by staff familiar with the drug's toxicities, preventing dangerous delays.
Subtle, early signs of serious T-cell engager toxicities like CRS and ICANS (e.g., mild confusion, headache) can be easily dismissed by patients. Effective management requires educating patients to report these symptoms immediately, as delaying can lead to severe outcomes, shifting focus to proactive patient behavior modification.
The standard of care for CRS has evolved. Instead of waiting for CRS to escalate, institutions now immediately administer dexamethasone and tocilizumab at the first sign of a fever (grade 1), finding it doesn't harm CAR T-cell expansion and improves safety.
Pulsed dexamethasone provides no overall response rate benefit compared to a standard prednisone taper in first-line ITP treatment. It may offer a slightly faster response (by about one day) but carries a higher risk of acute steroid complications, particularly psychosis in older adults.
Alex has bispecific patients keep flu and COVID tests at home because fever workup must still rule out infection. In one case, a patient had recurrent CRS fevers and later tested positive for flu B, with cough and congestion distinguishing the infection from her earlier fever-only CRS.
For drugs like enovalisib and gedatolisib with high rates of stomatitis, prophylactic use of a dexamethasone mouth rinse from day one is critical. This preventative measure significantly reduces the incidence and severity of painful oral sores, improving treatment tolerability.
Jennifer cites a retrospective glofitamab analysis where dexamethasone was associated with lower CRS or less need for additional support than other steroids. Its longer half-life and greater potency made dexamethasone the preferred steroid at Dana-Farber, although she notes the evidence is only retrospective for this drug class.
Granulocyte colony-stimulating factor (G-CSF) should be temporarily withheld in patients experiencing unresolved cytokine release syndrome. G-CSF administration can independently trigger low-grade fevers and acute inflammatory symptoms, obscuring whether the patient's presentation is an escalating immune toxicity, infection, or standard drug side effect.
Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.